bluuebunny/crossref_metadata_2025 huggingface dataset:
Improved similarity-based link prediction methods in trade networks by integrating community-based popularity
Authors: Liu Xing , Feng Xiaoling
Published: September 2024

Link prediction is a vital aspect of analyzing network evolution and identifying potential connections in complex networks. Previous studies have primarily focused on the information of common neighbors between nodes, often overlooking the inherent attributes of nodes. This study proposes community-based popularity, an attribute of nodes that considers changes in the neighborhood over time in conjunction with the community structure. Based on this attribute, we improve similarity-based link prediction methods. The experiments utilized unweighted directed networks from three distinct types of trade to evaluate the effectiveness of the improved link prediction methods. The training and probe sets were divided in chronological order. The experimental results show that the improved methods provide better link prediction results than the compared methods.
Global conformal symmetry in scalar-tensor theories
Authors: Babichev Eugeny , Charmousis Christos , Hassaine Mokhtar , Lecoeur Nicolas
Published: September 2024

We study a subclass of Horndeski gravity which has both global conformal and shift symmetries. Global symmetries are characterized by the presence of a conserved current which has been shown to be of particular importance for the integrability features of the theory at hand yielding numerous compact object solutions. We find the general conserved current associated to global conformal symmetry of Horndeski theories. We discuss some of its properties, how it can be conveniently broken by physically relevant terms and, show how it is related to that of shift symmetry when shift symmetry is present. Given our results, we consider a particular theory and demonstrate how the presence of symmetries provides integrability for the given black hole solution. We then find the charged extension of the solution thanks to the conformal invariance of the Maxwell action.
A New Symmetry-Based Transformer for Text Spotting in Person and Vehicle Re-Identification Images
Authors: Choudhury Aritro Pal , Palaiahnakote Shivakumara , Pal Umapada
Published: September 2024

Text spotting in person and vehicle re-identification images is complex due to the presence of multiple views of the same person and vehicle. Most existing models focus on text spotting in natural scene images, our work focuses on spotting in person and vehicle re-identification images. The rationale behind this work is that the person and the vehicles share symmetry properties and the bib number in the torso and license plate number in the vehicle are text. The method divides the input image into patches, and it explores vision transformation for encoding the patches into linear patches. The linearly embedded patches are fed to the feature similarity index step, which involves phase congruency and gradient magnitude to detect symmetric patches. The transformer is proposed to encode and capture textual information from the symmetry patches for text detection and recognition. The decoder receives the attention features from the encoder and fetches a multi-task head with the information about the detected and recognized text. The experiments on person and vehicle image benchmark, viz. (Person) Re-ID, RBNR, UFPR-ALPR and RodoSol datasets show significant improvement in performance when compared to other text spotting models. The effectiveness of the proposed model is validated by testing on the benchmark datasets, namely, ICDAR 2015, Total-Text and CTW1500 of natural scene images. Furthermore, cross-data validation shows the proposed method is independent of domains.
Artificial Intelligence and the Future of Evaluation: From Augmented to Automated Evaluation
Authors: Jacob Steve
Published: September 2024

The recent developments in artificial intelligence (AI) are revolutionizing professional practices across various professional fields, including evaluation. With its advanced automation and learning capabilities, AI is bringing significant changing to the way organizations and societies function. Evaluation is no exception to this trend, even though evaluators are adopting AI at a slower pace. This article examines ongoing applications that already improve and enhance the evaluation practice. We advance our discussion by exploring the potential impact of AI on the policy cycle. Subsequently, we analyze the potential incorporation of evaluation into autonomous AI systems that could design, implement, and evaluate public policies with minimal to no human supervision.
Social-sum-Mal: A Dataset for Abstractive Text Summarization in Malayalam
Authors: M Rahul Raj , Pankaj Dhanya S
Published: September 2024

Abstractive text summarization techniques for Malayalam language is still in its infancy. The lack of benchmarked datasets for this task is one of the constraints in developing and testing good models. Malayalam has seven nominal case forms, two nominal number forms, and three gender forms. It is subjected to extreme agglutination and inflection. Due to this, the translation of other text summarization datasets to Malayalam may not capture these case forms effectively. Therefore curation of datasets from scratch is highly demanded for specific text-processing applications in Malayalam. This article introduces a novel dataset designed specifically for advancing the field of automatic abstractive text summarization in Malayalam language. The dataset is curated to address the unique linguistic characteristics of the Malayalam language. It is called the
Social-sum-Mal dataset
, capable of addressing three different types of summarization tasks: long, extreme, and query-based summarizations. In addition, Social-sum-Mal can be extended for other applications like text classification, multi-document summarization, and question answering. To enhance the dataset transparency, a datasheet is created for Social-sum-Mal. Data accuracy and annotator biases are evaluated using proper testing strategies including Jaccard, cosine, and overlap similarities. The correctness of the dataset is further evaluated by comparing it with a deep learning based text summarization model.
Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies
Authors: Stagg John , Gutkind J. Silvio
Published: September 2024

The advent of cancer immunotherapy based on PD-1 and CTLA-4 immune checkpoint blockade (ICB) has revolutionized cancer treatment. However, many cancers do not respond to ICB, highlighting the urgent need for additional approaches to achieve durable cancer remission. The large family of G protein–coupled receptors (GPCRs) is the target of more than 30% of all approved drugs, but GPCRs have been underexploited in cancer immunotherapy. In this review, we discuss the central role of GPCRs in immune cell migration and function and describe how single-cell transcriptomic studies are illuminating the complexity of the human tumor immune GPCRome. These receptors include multiple GPCRs expressed in CD8 T cells that are activated by inflammatory mediators, protons, neurotransmitters, and metabolites that accumulate in the tumor microenvironment, thereby promoting T cell dysfunction. We also discuss new opportunities to target GPCRs as a multimodal approach to enhance the response to ICB for a myriad of human malignancies.
Proteomics and Bioinformatics Investigations Link Overexpression of FGF8 and Associated Hub Genes to the Progression of Ovarian Cancer and Poor Prognosis
Authors: Kumar Vikrant , Tomar Anil Kumar , Thapliyal Ayushi , Yadav Savita
Published: September 2024

Ovarian cancer’s asymptomatic nature, high recurrence rate, and resistance to platinum‐based chemotherapy highlight the need to find and characterize new diagnostic and therapeutic targets. While prior studies have linked aberrant expression of fibroblast growth factor 8 (FGF8) to various cancer types, its precise role has remained elusive. Recently, we observed that FGF8 silencing reduces the cancer‐promoting properties of ovarian cancer cells, and thus, this study aimed to understand how FGF8 regulates the development of ovarian cancer. LC‐MS/MS‐based quantitative proteomics analysis identified 418 DEPs, and most of them were downregulated in FGF8‐silenced ovarian cancer cells. Many of these DEPs are associated with cancer progression and unfavorable prognosis. To decipher the biological significance of DEPs, bioinformatics analyses encompassing gene ontology, pathway analysis, protein‐protein interaction networks, and expression analysis of hub genes were carried out. Hub genes identified in the FGF8 protein network were upregulated in ovarian cancer compared to controls and were linked to poor prognosis. Subsequently, the expression of hub genes was correlated with patient survival and regulation of the tumor microenvironment. Conclusively, FGF8 and associated hub genes help in the progression of ovarian cancer, and their overexpression may lead to higher immune infiltration, poor prognosis, and poor survival.
Multi‐UAV Cooperative Search for Moving Targets With Impaired Communication Using Improved Gray Wolf Optimizer
Authors: Zhan Jiaqi , Niu Chaoyang , Liu Wei , Wang Shiyu , Wan Xuanshen , Wang Yanyun
Published: September 2024

The study investigates the problem of collaborative target search by multiple unmanned aerial vehicles (UAVs) under the condition of communication information corruption. The problem involves the influence of target movement and environmental obstacles on the update of the UAV’s local target probability map (TPM), as well as communication information corruption among UAVs due to packet loss and resulting local information inconsistency. The objective is to efficiently plan paths for the UAV swarm to discover more targets. To address the above issues, this paper proposes the following methods. Firstly, an information diffusion model is introduced to simulate the TPM changes caused by target movement and the discovery of obstacles based on a two‐dimensional Gaussian distribution, thereby correcting the real‐time target information held by UAVs. Secondly, a radial basis function neural network (RBFNN) is employed to recover the corrupted information, and a weighted averaging method is used to fuse the information from multiple UAVs, achieving consensus among the UAVs. Lastly, the original gray wolf optimizer (GWO) is enhanced by incorporating strategies such as Levy flight and the nonlinear convergence factor. Subsequently, the improved GWO is integrated with the model predictive control (MPC) for UAV trajectory planning, enabling a more efficient search for optimal paths. Experimental results demonstrate that the proposed information recovery method outperforms the compared methods by 24.7% in terms of performance. The proposed comprehensive search approach shows higher efficiency in searching for more targets within a specified time, and it also exhibits advantages in terms of area coverage and other aspects.
Changes of Trigeminal Ganglion Neurons Innervating the Temporomandibular Joint in Chronic Pain Rat Model
Authors: Liu Wen , Jiang Henghua , Ke Jin , Liu Xin , Feng Yaping , Hou Jinsong , Long Xing
Published: September 2024

Background: Phenotype alterations of nociceptive neurons have been shown to be a key step in the pathogenesis of many pain‐related diseases. However, it is unclear if the characteristic changes of temporomandibular joint (TMJ) primary afferent neurons are related to the pathogenesis of temporomandibular joint osteoarthritis (TMJOA) chronic pain. This study aimed to determine the morphological and neurochemical changes in trigeminal ganglion (TG) neurons innervating the TMJ in TMJOA chronic pain rats.

Materials and Methods: Monosodium iodoacetate (MIA)‐induced TMJOA chronic pain rat model was established (n = 6), and saline was injected in rats of the control group (n = 6). TMJ primary afferent neurons were labeled with retrograde tracing (Dil). The spatial distribution and the expression of calcitonin gene‐related peptide (CGRP), isolectin B4 (IB4), and neurofilament 200 (NF200) of TMJ primary afferent neurons in TG were investigated using immunofluorescence. Intracellular calcium signaling was recorded by calcium imaging (n = 20).

Results: TMJ primary afferent neurons were located only in the V3 region of the TG from both saline‐ and MIA‐injected rats. The number of TG neurons innervating the TMJ was increased in MIA‐injected rats. Elevated number and intracellular calcium concentration of small‐ and medium‐sized instead of large‐sized Dil+ TG neurons were found in MIA‐injected rats. The upregulated expression of CGRP and IB4, but not NF200, in TG neurons innervating the rat TMJs was accompanied by TMJOA chronic pain.

Conclusion: This study suggests that sensitization of small‐ to medium‐sized Dil+ TG neurons and CGRP‐ and IB4‐positive Dil+ TG neurons might contribute to the development of TMJOA chronic pain in rats. This will provide valuable information for more efficient control of TMJOA chronic pain.
Exploring the Professional Identity and Practice Challenges of Lithuanian Dental Hygienists
Authors: Adomaitienė Rima , Andruskiene Jurgita , Albuquerque Teresa
Published: September 2024

Dental hygienist is the main provider of preventive oral care to promote and improve the oral health of individuals, families, and groups in society. However, the participation of dental hygienists in community outreach and public health programmes in Lithuania is limited, mainly due to the lack of institutional support and the unavailability of positions in public health initiatives, and the country’s population has insufficient access to cost‐effective oral health promotion services. This exploratory study aimed to analyse dental hygienists’ perception of their profession–to evaluate the scope of practice and professional challenges faced by dental hygienists in Lithuania, focusing on their provision of preventive dental care and educational roles. This study is one part of a prospective study which was conducted in 2021. By using the qualitative approach, with a semistructured interview, the dental hygienists’ experience, towards understanding their duties and concept of profession, was collected. Interviews were conducted with seven dental hygienists. A thematic analysis of data from the interview was performed. Three themes were extracted from the contents: (1) concept of dental hygienist’s profession, (2) personal qualities, and (3) practical activities carried out by dental hygienists. The study results showed dental hygienists in Lithuania have a broad role focusing on patient care, educational activities, and preventive methods in line with European standards. Key attributes such as communication skills, diligence, and empathy are essential for effective practice, ensuring quality patient care and professional standards. Despite fulfilling nationally defined roles, dental hygienists seek expanded competencies and greater involvement in clinical and preventive care.
Using MSPG to Suppress Flooding in the Data‐Link Layer for SDN
Authors: Song Guangjia , Wang Hui , Hu Jianhua
Published: September 2024

The media access control (MAC) address is the basis of frame forwarding in data‐link layer. When MAC missing occurs in the software‐defined network (SDN), the processing method is the same as that of Ethernet, which is also broadcast. The broadcast will spread and cover part or even the entire network, result in a large number of frames, which leads to a sharp increase in network traffic, even cause congestion. To suppress the layer‐2 flooding, a new frame forwarding method is proposed, namely, multidevice search and path generation (MSPG). New approach will search multiple devices when MAC missing occurs and calculate a forwarding path; a set of flow table is generated to restrain the switch from broadcasting. Experiments and analysis show that in comparison with the existing frame forwarding methods in SDN, MSPG can effectively suppress flooding, greatly reduce the network load, minimize the traffic between data plane and control plane when MAC missing occurs, and reduce energy consumption significantly. The MSPG’s path calculation and flow dispatch method also decrease the forwarding delay and are more suitable for large‐scale network.
Supplementary Tables 4-7 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Authors: Jeon Seung Hyuck , You Gihoon , Park Junsik , Chung Youseung , Park Kyungjin , Kim Hyunjoo , Jeon Jaehyoung , Kim Youngkwang , Son Woo-Chan , Jeong Da Som , Shin Eui-Cheol , Lee Jung-Yun , Han Dai Hoon , Jung Jaeho , Park Su-Hyung
Published: September 2024

Supplementary Tables 4-7
Supplementary Tables 1-3 from Anti–4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade
Authors: Jeon Seung Hyuck , You Gihoon , Park Junsik , Chung Youseung , Park Kyungjin , Kim Hyunjoo , Jeon Jaehyoung , Kim Youngkwang , Son Woo-Chan , Jeong Da Som , Shin Eui-Cheol , Lee Jung-Yun , Han Dai Hoon , Jung Jaeho , Park Su-Hyung
Published: September 2024

Supplementary Tables 1-3
Supplementary Table S2 from A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Authors: Furuse Junji , Ikeda Masafumi , Ueno Makoto , Furukawa Masayuki , Morizane Chigusa , Takehara Tetsuo , Nishina Tomohiro , Todaka Akiko , Okano Naohiro , Hara Kazuo , Nakai Yousuke , Ohkawa Kazuyoshi , Sasaki Takashi , Sugimori Kazuya , Yokoyama Naoyuki , Yamamoto Kouji
Published: September 2024

Supplementary Table S2. Disease control rate (DCR).
Supplementary Figure S5 from A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Authors: Furuse Junji , Ikeda Masafumi , Ueno Makoto , Furukawa Masayuki , Morizane Chigusa , Takehara Tetsuo , Nishina Tomohiro , Todaka Akiko , Okano Naohiro , Hara Kazuo , Nakai Yousuke , Ohkawa Kazuyoshi , Sasaki Takashi , Sugimori Kazuya , Yokoyama Naoyuki , Yamamoto Kouji
Published: September 2024

Supplementary Figure S5. Uptake of nanvuranlat into cholangiocytes via OATP1A2.
Supplementary Figure S3 from A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Authors: Furuse Junji , Ikeda Masafumi , Ueno Makoto , Furukawa Masayuki , Morizane Chigusa , Takehara Tetsuo , Nishina Tomohiro , Todaka Akiko , Okano Naohiro , Hara Kazuo , Nakai Yousuke , Ohkawa Kazuyoshi , Sasaki Takashi , Sugimori Kazuya , Yokoyama Naoyuki , Yamamoto Kouji
Published: September 2024

Supplementary Figure S3. Disease Control Rate by category of response.
Supplementary Figure S1 from A Phase II Placebo-Controlled Study of the Effect and Safety of Nanvuranlat in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy
Authors: Furuse Junji , Ikeda Masafumi , Ueno Makoto , Furukawa Masayuki , Morizane Chigusa , Takehara Tetsuo , Nishina Tomohiro , Todaka Akiko , Okano Naohiro , Hara Kazuo , Nakai Yousuke , Ohkawa Kazuyoshi , Sasaki Takashi , Sugimori Kazuya , Yokoyama Naoyuki , Yamamoto Kouji
Published: September 2024

Supplementary Figure S1. The CONSORT flow diagram and NAT2 phenotype distribution.
Supplementary Figure S2 from Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
Authors: Teijeira Alvaro , Garasa Saray , Ochoa Maria C. , Sanchez-Gregorio Sandra , Gomis Gabriel , Luri-Rey Carlos , Martinez-Monge Rafael , Pinci Beatrice , Valencia Karmele , Palencia Belen , Barbés Benigno , Bolaños Elixabet , Azpilikueta Arantza , García-Cardosa Marina , Burguete Javier , Eguren-Santamaría Iñaki , Garate-Soraluze Eneko , Berraondo Pedro , Perez-Gracia Jose L. , de Andrea Carlos E. , Rodriguez-Ruiz Maria E. , Melero Ignacio
Published: September 2024

Supplementary Figure S2. Radiation-induced NETs increase metastases to the lung in a spontaneously metastatic model.
Supplementary Tables S1-S12 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Table 1: Clinicopathological Features, Patient Cohort (n=220) Suppl. Table 2: Gene targets of the mRNA ISH analysis Suppl Table 3: Proteins of the Immune Cell Profiling Core Suppl. Table 4: mRNA data across the tumor center and invasive tumor front of HI-PDACs, with FDR-corrected P-values Suppl. Table 5: mRNA data across the tumor center and invasive tumor front of LI-PDACs, with FDR-corrected P-values Suppl. Table 6: Protein data across the tumor center and invasive tumor front of HI-PDACs with FDR-corrected P-values Suppl. Table 7: Protein data across the tumor center and invasive tumor front of LI-PDACs with FDR-corrected P-values Suppl. Table 8: Most common genetic alterations Suppl. Table 9: Distribution of the main immune cell infiltrates across PDAC immune subgroups and tumor areas. Percentage average values of all ROIs for this area. Suppl. Table 10 Suppl. Table 11: Distance* of immune cells to tumor cells across PDAC immune subgroups. Median values are in μm (range). Suppl. Table 12: Main immunological findings across the PDAC immune subgroups
Supplementary Figure S8 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S8: Pie charts depicting the distribution of the percentage of the glandular component (Gl) and tumor budding categories (Bd1 - Bd3) across the immune PDAC groups.
Supplemental Figure S4 from Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs
Authors: Stinson Jordan A. , Barbosa Matheus Moreno P. , Sheen Allison , Momin Noor , Fink Elizabeth , Hampel Jordan , Selting Kim A. , Kamerer Rebecca L. , Bailey Keith L. , Wittrup Karl D. , Fan Timothy M.
Published: September 2024

Supplemental Figure S4. IFNγ and IL10 response to cytokine-only or RT-only treatment.
Supplementary Figure S7 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S7: Kaplan-Meier curve depicting survival differences between HI-PDACs and LI-PDACs.
Supplementary Figure S6 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S6: Protein expression of the immune cell component (PanCK-CD45+) across HI-PDACs and LI-PDACs (220 cases)
Supplementary Figure S3 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S3: mRNA expression across the tumor center and the invasive tumor front of HI-PDACs
Supplementary Figure S2 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S2: : A: Schematic representation of PDAC including the area of the invasive tumor front (500µm on each side of the border, red line), showing the selection of the tumor areas (each four) from the tumor center and the invasive tumor front. B: Higher magnification of the selected areas from the tumor center and the invasive front stained by fluorescent imaging using pancytokeratin (PanCK, green) and CD45 (red) to define the spatial compartments: PanCK+CD45- defines the tumor cell compartment and PanCK-CD45+ defines the leukocyte compartment (x200).
Supplementary Figure S11 from Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic Cancer
Authors: Karamitopoulou Eva , Wenning Anna S. , Acharjee Animesh , Aeschbacher Pauline , Marinoni Ilaria , Zlobec Inti , Gloor Beat , Perren Aurel
Published: September 2024

Suppl. Figure S11: Immunofluorescent images of HI-PDAC and LI-PDAC from the area of the tumor center and the tumor front depicting the antithetical gradients of the density of immune infiltrates across tumor areas. Tumor cells stained green and immune cells magenda. The nuclear counterstain (DAPI) is blue. Multiplex immuno-fluorescence (mIF) x200.
Figure S2 from Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody–Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
Authors: Iida Naoko , Imai Mitsuho , Okamoto Wataru , Kato Takeshi , Esaki Taito , Kato Ken , Komatsu Yoshito , Yuki Satoshi , Masuishi Toshiki , Nishina Tomohiro , Ebi Hiromichi , Taniguchi Hiroya , Nonomura Norio , Sunakawa Yu , Shiozawa Manabu , Yamazaki Kentaro , Boku Shogen , Bando Hideaki , Shiraishi Yuichi , Kobayashi Maki , Goto Hiroki , Sato Akihiro , Fujii Satoshi , Yoshino Takayuki , Nakamura Yoshiaki
Published: September 2024

Figure S2
Table S1 from Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
Authors: Grazini Ursula , Markovets Aleksandra , Ireland Lucy , O’Neill Daniel , Phillips Benjamin , Xu Man , Pfeifer Matthias , Vaclova Tereza , Martin Matthew J. , Bigot Ludovic , Friboulet Luc , Hartmaier Ryan , Cuomo Maria E. , Barry Simon T. , Smith Paul D. , Floc’h Nicolas
Published: September 2024

Table S1: Statistical comparison between treatment arms for the on-treatment phase in PC9 PIK3CAm xenograft models described in Figure 5E.
Supplementary Table S1 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

Supplementary Table S1. Baseline Characteristics of MM Patients before BCMA CAR-T Therapy.
Supplementary Figure S6 from Reconstitution of the Multiple Myeloma Microenvironment Following Lymphodepletion with BCMA CAR-T Therapy
Authors: Yang Yazi , Qin Sen , Yang Mengyu , Wang Ting , Feng Ru , Zhang Chunli , Zheng Enrun , Li Qinghua , Xiang Pengyu , Ning Shangyong , Xu Xiaodong , Zuo Xin , Zhang Shuai , Yun Xiaoya , Zhou Xuehong , Wang Yue , He Lin , Shang Yongfeng , Sun Luyang , Liu Hui
Published: September 2024

Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.
Supplementary Table S3 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Prognostic value of ctDNA by cut point
Supplementary Table S1 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Patient characteristics of the biomarker-evaluable population
Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Prognostic value of on-treatment ctDNA TF detection and 30% PSA reduction
Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Prognostic value of 90% PSA reduction
Supplementary Figure S7 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Prognostic value of 30% PSA reduction
Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

ctDNA tumor fraction to prognosticate overall survival on enzalutamide post-abiraterone by treatment arm
Supplementary Figure S2 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Authors: Sweeney Christopher J. , Petry Russell , Xu Chang , Childress Merrida , He Jie , Fabrizio David , Gjoerup Ole , Morley Samantha , Catlett Timothy , Assaf Zoe J. , Yuen Kobe , Wongchenko Matthew , Shah Kalpit , Gupta Pratyush , Hegde Priti , Pasquina Lincoln W. , Mariathasan Sanjeev , Graf Ryon P. , Powles Thomas
Published: September 2024

Overall survival by biomarker evaluability
Supplementary Figure S1 from CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma
Authors: Pobbati Ajaybabu V. , Burtscher Ashley , Rajaram Siva Nandini , Hallett Andrea , Romigh Todd , Che Kepeng , Zhao Bin , Coker Jesse A. , Wang Nancy , Stauffer Shaun R. , Rubin Brian P.
Published: September 2024

Figure S1. Dose-response curves of triptonide, triptolide, and dBET6
Table S2 from Oral and Gut Microbiome Alterations in Oral Chronic GVHD Disease: Results from Close Assessment and Testing for Chronic GVHD (CATCH Study)
Authors: Rashidi Armin , Pidala Joseph , Hamilton Betty K. , Pavletic Steven Z. , Kim Katie , Zevin Alex , Mays Jacqueline W. , Lee Stephanie J.
Published: September 2024

Differential abundance analysis of oral microbiota at T1 vs. T0 timepoint
Supplementary Data 1 from A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Authors: Grommes Christian , Nandakumar Subhiksha , Schaff Lauren R. , Gavrilovic Igor , Kaley Thomas J. , Nolan Craig P. , Stone Jacqueline , Thomas Alissa A. , Tang Sarah S. , Wolfe Julia , Bozza Alexis , Wongchai Venissala , Hyde Alisson , Barrett Emma , Lynch Elizabeth A. , Madzsar Juli T. , Lin Andrew , Piotrowski Anna F. , Pentsova Elena , Francis Jasmine H. , Hatzoglou Vaios , Schultz Nikolaus , Reiner Anne S. , Panageas Katherine S. , DeAngelis Lisa M. , Mellinghoff Ingo K.
Published: September 2024

Additional data
Supplementary Figure S3 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Authors: Grewal Eric P. , Richardson Leland G.K. , Sun Jing , Ramapriyan Rishab , Martinez-Lage Maria , Miller Julie J. , Carter Bob S. , Cahill Daniel P. , Curry William T. , Choi Bryan D.
Published: September 2024

Supplementary Figure 3. Effect of IDH inhibition on intratumoral macrophage population in murine IDH-mutant glioma
Supplementary Figure S2 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Authors: Grewal Eric P. , Richardson Leland G.K. , Sun Jing , Ramapriyan Rishab , Martinez-Lage Maria , Miller Julie J. , Carter Bob S. , Cahill Daniel P. , Curry William T. , Choi Bryan D.
Published: September 2024

Supplementary Figure 2. Quantitation of additional myeloid cell subtypes in murine IDH-wildtype and IDH-mutant glioma
Supplementary Figure S1 from Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma
Authors: Grewal Eric P. , Richardson Leland G.K. , Sun Jing , Ramapriyan Rishab , Martinez-Lage Maria , Miller Julie J. , Carter Bob S. , Cahill Daniel P. , Curry William T. , Choi Bryan D.
Published: September 2024

Supplementary Figure 1. Flow cytometry gating strategy for quantifying murine intratumoral myeloid cell populations
Supplementary Table S3 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Table S3. Post hoc analysis for mOS, with and without patients treated with trastuzumab.
Table 1 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Clinicopathological parameters and preclinical models generated from patients with PMP enrolled in the study.
Supplementary Table 6 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Table 6. Validation of druggable targets in the tumor samples from PMP patients by droplet digital PCR (ddPCR).
Supplementary Figure S9 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Figure S9. Correlation between the induced levels of HER2-specific IgG antibodies, and their binding to HER2-expressing cells and intracellular phosphorylation inhibition.
Supplementary Table 5 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Table 5. Mutational status of the PMP organoid models used in the study.
Supplementary Table 4 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Table 4. Correlation of PMP markers in patient samples and their corresponding organoid model.
Supplementary Figure S7 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Authors: Tobias Joshua , Maglakelidze Marina , Andrić Zoran , Ryspayeva Dinara , Bulat Iurie , Nikolić Ivan , Petrović Zoran , Chawla Tanuj , Nagarkar Rajnish , Garner-Spitzer Erika , Zielinski Christoph C. , Chong Leslie Mi Ok , Nixon Bonnie , Ede Nicholas J. , Yavrom Sharon , Kundi Michael , Wiedermann Ursula
Published: September 2024

Supplementary Figure S7. Correlation between the induced HER2-specific and P467-specific total IgG antibodies in each patient.
Supplementary Figure 9 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Figure 9. BRAF inhibitors reduce tumor mass in an orthotopic BRAFV600E PMP-PDX model.
Supplementary Figure 8 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Figure 8. Treatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600E PMP-PDX tumors without impacting in apoptosis.
Supplementary Figure 7 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Supplementary Figure 7. BRAF signaling pathway inhibition in a subcutaneous BRAFV600E PMP-PDX model.
Figure 3 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Treatment with BRAF inhibitor is enough to block RAS/ERK signaling pathway and reduce cell viability in PMP models. BRAFWT (T70) or BRAFV600E (CTAX34) colorectal cancer PDXO and BRAFV600E PMP PDXO (PMP5.1) or PDO (PMP5.2) derived from two different peritoneal metastasis from PMP patient 5 treated with vehicle, mitomycin C 150 ng/mL, cetuximab 100 μg/mL, encorafenib 1 μmol/L, doublet (encorafenib + cetuximab). A and B, Cell viability (A) and caspase 3/7 activation (B) were measured after 5 days or 48 hours on treatment, respectively. Mean ± SD of triplicates is shown. Significant differences were assessed using one-way ANOVA and Dunnett’s multiple comparisons tests compared to control (*, P value < 0.05; **, P value < 0.01; ***, P value < 0.001; ****, P value < 0.0001). C and D, Western blot analysis of phospho-ERK, phospho-EGFR, ERK, and EGFR was performed after 30 minutes or 24 hours on treatment. Quantification of phospho-EGFR/EGFR (C) and phospho-ERK/ERK (D) ration in all the samples. r.u, relative units. PMP, Pseudomyxoma peritonei; CRC, Colorectal cancer; PDO, Patient-derived organoid; PDXO, Patient-derived xenografts organoid.
Figure 2 from Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei
Authors: Martínez-Quintanilla Jordi , Cabot Débora , Sabia Doménico , Arqués Oriol , Vergés Jordi , Chicote Irene , Bijelic Lana , Cabellos Laia , Alcántara Anna M. , Ramos Isabel , Barrios Pedro , Crusellas Oriol , Palacio Lina M. , Cámara Juan A. , Barriuso Jorge , Jiménez Juan J. , Muñoz-Torres Pau , Nonell Lara , Flores Raquel , Médico Enzo , Guaglio Marcello , Ros Javier , Élez Elena , Tabernero Josep , Aziz Omer , Deraco Marcello , Palmer Héctor G. , Giovanna Chiorino , Francesco Mazzarotto , Manuela Gariboldi , Luca Varinelli , Tommaso Cavalleri , Bipasha Chakrabarty , Raghavendar Nagaraju , Patrick Caswell , Milly McAllister
Published: September 2024

Genomic characterization of preclinical models and intra-abdominal mucin reveal druggable targets in PMP. A, Oncoplot from exome sequencing analysis from 28 PMP-PDO or PMP-PDXO models derived from 20 patients. The most common mutated genes in all the models are presented and compared with the cohort of patients with colorectal cancer from the TCGA COADREAD, a cohort of patients with appendiceal tumors from the study of Ang and colleagues and a collection of PMP paraffin samples from the study of Alakus and colleagues. Patient and sample number, primary vs. peritoneal disease, and grade are indicated in the top. Genomic alterations are shown in different colors in the oncoplot. The percentage of PMP preclinical models with the specific mutations is indicated on the right site of the oncoplot. Finally, specific mutations in the KRAS gene are shown in the bottom site of the panel. B, ddPCR for KRASG12C using genomic DNA extracted from intra-abdominal mucin biopsy of PMP29 (sample PMP29.1; left), negative control (middle), and positive control (right). The study was performed in duplicates. Blue spots and green spots represent positive events for KRASG12C (top graph) and KRASWT genotype (bottom graph), respectively. The threshold line was determined by the control samples to separate the two clusters of negative and positive droplets. PMP, Pseudomyxoma peritonei; CRC, Colorectal cancer; PDO, Patient-derived organoid; PDXO, Patient-derived xenografts organoid; LAMN, low-grade appendiceal mucinous neoplasm; HAMN, high-grade appendiceal mucinous neoplasm; Grade 1, low-grade mucinous carcinoma peritonei; Grade 2, high-grade mucinous carcinoma peritonei; Grade 3, high-grade mucinous carcinoma peritonei with or without signet ring cells.